Anavex Life Sciences Corp.
AVXLAnavex Life Sciences Corp. in brief
Anavex Life Sciences Corp. is a listed company in the Biotechnology industry, based in New York, New York, USA. Its market value was $123 M on 26 October 2026, which makes it the 17,983rd largest listed company in the world and the 3,410th largest in the USA on this site. It employs about 25 people and Terrie Kellmeyer is its chief executive. Its shares trade under the symbol AVXL (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Anavex Life Sciences Corp.
Anavex Life Sciences is a person-focused, biopharmaceutical company dedicated to therapeutic discovery and development of targeted CNS treatments. The headquarters is in USA.
Anavex Life Sciences Corp. timeline
- 2005
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2007
- ✎Renamed Anavex Life Sciences Corp.Formerly Thrifty Printing Inc..
Events of Anavex Life Sciences Corp. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,431 (Jan 2020) · #2,800 (Jan 2021) · #2,403 (Jan 2022) · #2,353 (Dec 2022) · #2,457 (Jul 2023) · #2,479 (Jan 2024) · #1,318 (Mar 2026) · #2,874 (Aug 2026) · #3,323 (Oct 2026) · #3,414 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 1.3×
- Free cash flow yield
- -2.2%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -48.9%
- Liabilities / assets
- 8.6%
- Net debt
- $-15M
- Profit per employee
- $-1.9 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Sep 2025 | — | — | $-51M | $-46M | — |
| Sep 2024 | — | — | $-53M | $-43M | — |
| Sep 2023 | — | — | $-56M | $-48M | — |
| Sep 2022 | — | — | $-51M | $-48M | — |
| Sep 2021 | — | — | $-42M | $-38M | — |
| Sep 2020 | — | — | $-31M | $-26M | — |
| Sep 2019 | — | — | — | $-26M | — |
| Sep 2018 | — | — | — | $-17M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Sep 2025 | $-39M | — | — | $-0.54 | — |
| Sep 2024 | $-31M | — | — | $-0.52 | — |
| Sep 2023 | $-28M | — | — | $-0.60 | — |
| Sep 2022 | $-24M | — | — | $-0.62 | — |
| Sep 2021 | $-30M | — | — | $-0.54 | — |
| Sep 2020 | $-21M | — | — | $-0.45 | — |
| Sep 2019 | $-19M | — | — | $-0.54 | — |
| Sep 2018 | $-13M | — | — | $-0.39 | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $8M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 3, 20268-KCurrent reportDirectors or officers changed
- Nov 2, 20268-KCurrent reportDirectors or officers changed · Other events
- Oct 20, 20268-KCurrent reportOther events
- Oct 15, 20268-KCurrent reportOther events
- Sep 28, 20268-KCurrent reportChange in control · Shareholder vote
- Sep 9, 20268-KCurrent reportOther events
- Sep 2, 20268-KCurrent reportOther events
- Aug 28, 202610-QQuarterly report · period to Jun 2026
- Aug 28, 202610-QQuarterly report · period to Mar 2026
- Aug 28, 202610-Q/AQuarterly report (amended) · period to Dec 2025
- Aug 28, 202610-K/AAnnual report (amended) · period to Sep 2025
- Aug 25, 20268-KCurrent reportResults of operations
Official filings of Anavex Life Sciences Corp. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-51 M
- Net income
- $-46 M
For year ending September-2025 · source: SEC filing
Balance sheet
- Total assets
- $104 M
- Total liabilities
- $9 M
- Total equity
- $95 M
As of September-2025
Top 100 institutional investors in Anavex Life Sciences Corp.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 8,144,147 | +88,519 (+1.10%) | 8.79% | $16 M | Nov 13, 2026 |
| 2 | Vanguard Capital Management LLC | 4,094,908 | +40,319 (+0.99%) | 4.42% | $8 M | Nov 13, 2026 |
| 3 | GMT Capital Corp | 2,704,364 | New | 2.92% | $5 M | Nov 16, 2026 |
| 4 | Federated Hermes, Inc. | 2,585,094 | +1,513,285 (+141.19%) | 2.79% | $5 M | Nov 12, 2026 |
| 5 | Two Sigma Investments, LP | 2,336,420 | -710,118 (-23.31%) | 2.52% | $5 M | Nov 16, 2026 |
| 6 | Geode Capital Management, LLC | 2,275,241 | -132,232 (-5.49%) | 2.45% | $5 M | Nov 6, 2026 |
| 7 | State Street Corp | 1,958,409 | +35,639 (+1.85%) | 2.11% | $4 M | Nov 12, 2026 |
| 8 | Vanguard Portfolio Management LLC | 898,456 | -50,177 (-5.29%) | 0.97% | $2 M | Nov 13, 2026 |
| 9 | Summit Financial, LLC | 889,069 | -20,361 (-2.24%) | 0.96% | $2 M | Nov 12, 2026 |
| 10 | Goldman Sachs Group Inc | 889,066 | -1,568 (-0.18%) | 0.96% | $2 M | Nov 16, 2026 |
| 11 | Charles Schwab Investment Management Inc | 886,987 | +152,192 (+20.71%) | 0.96% | $2 M | Nov 16, 2026 |
| 12 | Barclays PLC | 868,259 | +114,033 (+15.12%) | 0.94% | $2 M | Nov 6, 2026 |
| 13 | Northern Trust Corp | 789,290 | +4,796 (+0.61%) | 0.85% | $2 M | Nov 16, 2026 |
| 14 | Marshall Wace, LLP | 758,238 | -131,285 (-14.76%) | 0.82% | $2 M | Nov 13, 2026 |
| 15 | Vanguard Fiduciary Trust Co | 625,946 | +4,495 (+0.72%) | 0.68% | $1 M | Nov 13, 2026 |
| 16 | Citadel Advisors LLC | 548,819 | +219,704 (+66.76%) | 0.59% | $1 M | Nov 16, 2026 |
| 17 | Private Advisor Group, LLC | 432,000 | -72,000 (-14.29%) | 0.47% | $1 M | Nov 10, 2026 |
| 18 | UBS Group AG | 430,843 | -189,531 (-30.55%) | 0.46% | $1 M | Nov 10, 2026 |
| 19 | Morgan Stanley | 414,151 | +219,188 (+112.43%) | 0.45% | $1 M | Nov 13, 2026 |
| 20 | Bank Of America Corp /de/ | 405,033 | -249,262 (-38.10%) | 0.44% | $1 M | Nov 16, 2026 |
| 21 | LPL Financial LLC | 357,220 | -48,889 (-12.04%) | 0.39% | $1 M | Nov 6, 2026 |
| 22 | Stifel Financial Corp | 352,975 | +20,378 (+6.13%) | 0.38% | $1 M | Nov 12, 2026 |
| 23 | Wellington Management Group LLP | 331,133 | New | 0.36% | $1 M | Nov 16, 2026 |
| 24 | Bank of New York Mellon Corp | 297,437 | +9,238 (+3.21%) | 0.32% | $1 M | Nov 5, 2026 |
| 25 | Nuveen, LLC | 226,138 | +43,416 (+23.76%) | 0.24% | $0 M | Nov 10, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Apella Capital, LLC | 223,006 | -4,989 (-2.19%) | 0.24% | $0 M | Oct 8, 2026 |
| 27 | AQR Capital Management LLC | 214,266 | -748,748 (-77.75%) | 0.23% | $0 M | Nov 16, 2026 |
| 28 | Susquehanna International Group, LLP | 202,280 | -117,249 (-36.69%) | 0.22% | $0 M | Nov 16, 2026 |
| 29 | D. E. Shaw & Co., Inc. | 191,638 | +76,176 (+65.97%) | 0.21% | $0 M | Nov 16, 2026 |
| 30 | Canada Pension Plan Investment Board | 187,300 | -14,500 (-7.19%) | 0.20% | $0 M | Nov 16, 2026 |
| 31 | PVG Asset Management Corp | 155,207 | -172,137 (-52.59%) | 0.17% | $0 M | Oct 19, 2026 |
| 32 | Los Angeles Capital Management LLC | 138,940 | +42,015 (+43.35%) | 0.15% | $0 M | Nov 12, 2026 |
| 33 | Invesco Ltd. | 138,913 | +28,965 (+26.34%) | 0.15% | $0 M | Nov 12, 2026 |
| 34 | Voleon Capital Management LP | 136,626 | +73,121 (+115.14%) | 0.15% | $0 M | Nov 16, 2026 |
| 35 | Alliancebernstein L.P. | 135,930 | -10,370 (-7.09%) | 0.15% | $0 M | Nov 16, 2026 |
| 36 | Jpmorgan Chase & Co | 130,130 | +83,363 (+178.25%) | 0.14% | $0 M | Nov 12, 2026 |
| 37 | Alps Advisors Inc | 121,938 | +27,887 (+29.65%) | 0.13% | $0 M | Nov 3, 2026 |
| 38 | Bridgeway Capital Management, LLC | 120,938 | -2,062 (-1.68%) | 0.13% | $0 M | Nov 16, 2026 |
| 39 | Empowered Funds, LLC | 120,938 | New | 0.13% | $0 M | Nov 13, 2026 |
| 40 | Rhumbline Advisers | 110,546 | -1,503 (-1.34%) | 0.12% | $0 M | Nov 10, 2026 |
| 41 | XTX Topco Ltd | 94,507 | +61,791 (+188.87%) | 0.10% | $0 M | Nov 16, 2026 |
| 42 | HSBC Holdings PLC | 93,936 | -8,989 (-8.73%) | 0.10% | $0 M | Nov 16, 2026 |
| 43 | Hikari Power Ltd | 85,585 | 0 (0.00%) | 0.09% | $0 M | Oct 30, 2026 |
| 44 | Price T Rowe Associates Inc /MD/ | 83,666 | +16,948 (+25.40%) | 0.09% | $0 M | Nov 16, 2026 |
| 45 | Renaissance Technologies LLC | 79,999 | New | 0.09% | $0 M | Nov 12, 2026 |
| 46 | Point72 Asset Management, L.P. | 77,502 | -79,984 (-50.79%) | 0.08% | $0 M | Nov 16, 2026 |
| 47 | PNC Financial Services Group, Inc. | 72,401 | +5,779 (+8.67%) | 0.08% | $0 M | Nov 6, 2026 |
| 48 | Deutsche Bank AG\ | 69,291 | -10,041 (-12.66%) | 0.07% | $0 M | Nov 6, 2026 |
| 49 | Cerity Partners LLC | 67,125 | -21,231 (-24.03%) | 0.07% | $0 M | Nov 13, 2026 |
| 50 | 180 Wealth Advisors, LLC | 63,690 | -7,340 (-10.33%) | 0.07% | $0 M | Nov 3, 2026 |
| 51 | LexAurum Advisors, LLC | 61,135 | -3,915 (-6.02%) | 0.07% | $0 M | Oct 19, 2026 |
| 52 | Cetera Investment Advisers | 55,845 | -19,276 (-25.66%) | 0.06% | $0 M | Nov 13, 2026 |
| 53 | Ameriprise Financial Inc | 54,490 | -4,605 (-7.79%) | 0.06% | $0 M | Nov 16, 2026 |
| 54 | Jain Global LLC | 51,915 | +29,913 (+135.96%) | 0.06% | $0 M | Nov 16, 2026 |
| 55 | Bolton Securities Corporation | 50,000 | 0 (0.00%) | 0.05% | $0 M | Nov 12, 2026 |
| 56 | BNP Paribas Financial Markets | 48,088 | +18,772 (+64.03%) | 0.05% | $0 M | Nov 12, 2026 |
| 57 | Hayek Kallen Investment Management | 47,709 | +600 (+1.27%) | 0.05% | $0 M | Nov 13, 2026 |
| 58 | Wells Fargo & Company/mn | 46,822 | -69,852 (-59.87%) | 0.05% | $0 M | Nov 16, 2026 |
| 59 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 44,731 | +2,278 (+5.37%) | 0.05% | $0 M | Nov 16, 2026 |
| 60 | Creative Planning | 41,809 | -17,971 (-30.06%) | 0.05% | $0 M | Nov 2, 2026 |
| 61 | Geneos Wealth Management Inc. | 41,800 | -6,300 (-13.10%) | 0.05% | $0 M | Nov 9, 2026 |
| 62 | Bank Of Montreal /can/ | 41,664 | +2,154 (+5.45%) | 0.04% | $0 M | Nov 9, 2026 |
| 63 | Sheets Smith Wealth Management | 40,712 | -30,547 (-42.87%) | 0.04% | $0 M | Oct 16, 2026 |
| 64 | Snowden Capital Advisors LLC | 40,449 | -35 (-0.09%) | 0.04% | $0 M | Nov 16, 2026 |
| 65 | Foster Victor Wealth Advisors, LLC | 39,925 | 0 (0.00%) | 0.04% | $0 M | Oct 21, 2026 |
| 66 | Squarepoint Ops LLC | 38,861 | +438 (+1.14%) | 0.04% | $0 M | Nov 9, 2026 |
| 67 | NewEdge Advisors, LLC | 37,919 | +1,029 (+2.79%) | 0.04% | $0 M | Nov 13, 2026 |
| 68 | Opus Capital Group, LLC | 37,700 | 0 (0.00%) | 0.04% | $0 M | Oct 30, 2026 |
| 69 | Envestnet Asset Management Inc | 36,695 | -109,635 (-74.92%) | 0.04% | $0 M | Nov 16, 2026 |
| 70 | MetLife Investment Management, LLC | 34,881 | -16,746 (-32.44%) | 0.04% | $0 M | Nov 16, 2026 |
| 71 | Vanguard Global Advisers, LLC | 34,532 | +424 (+1.24%) | 0.04% | $0 M | Nov 13, 2026 |
| 72 | Russell Investments Group, Ltd. | 31,540 | +8,050 (+34.27%) | 0.03% | $0 M | Nov 6, 2026 |
| 73 | Forum Financial Management, LP | 30,100 | 0 (0.00%) | 0.03% | $0 M | Oct 16, 2026 |
| 74 | VestGen Advisors, LLC | 30,030 | New | 0.03% | $0 M | Oct 27, 2026 |
| 75 | Osaic Holdings, Inc. | 29,901 | -4,565 (-13.24%) | 0.03% | $0 M | Nov 12, 2026 |
| 76 | Choreo, LLC | 29,709 | 0 (0.00%) | 0.03% | $0 M | Oct 28, 2026 |
| 77 | Independent Advisor Alliance | 28,568 | -2,000 (-6.54%) | 0.03% | $0 M | Nov 10, 2026 |
| 78 | Dimensional Fund Advisors LP | 27,238 | 0 (0.00%) | 0.03% | $0 M | Nov 4, 2026 |
| 79 | Manufacturers Life Insurance Company, The | 26,706 | +820 (+3.17%) | 0.03% | $0 M | Nov 13, 2026 |
| 80 | Beacon Pointe Advisors, LLC | 23,185 | 0 (0.00%) | 0.03% | $0 M | Nov 16, 2026 |
| 81 | Police & Firemen's Retirement System of New Jersey | 23,092 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 82 | Gladstone Institutional Advisory LLC | 22,931 | +5,260 (+29.77%) | 0.02% | $0 M | Nov 13, 2026 |
| 83 | Simplex Trading, LLC | 21,666 | -11,223 (-34.12%) | 0.02% | $0 M | Nov 4, 2026 |
| 84 | FMR LLC | 21,524 | -38,500 (-64.14%) | 0.02% | $0 M | Nov 10, 2026 |
| 85 | Ieq Capital, LLC | 20,649 | -93,599 (-81.93%) | 0.02% | $0 M | Nov 10, 2026 |
| 86 | Dana Investment Advisors, Inc. | 20,406 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 87 | State Board Of Administration Of Florida Retirement System | 20,345 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 88 | Hamilton Point Investment Advisors, LLC | 20,300 | 0 (0.00%) | 0.02% | $0 M | Nov 3, 2026 |
| 89 | Brevan Howard Capital Management LP | 19,506 | New | 0.02% | $0 M | Nov 16, 2026 |
| 90 | Voya Investment Management LLC | 19,435 | 0 (0.00%) | 0.02% | $0 M | Nov 10, 2026 |
| 91 | Royal Bank Of Canada | 19,418 | +15,797 (+436.26%) | 0.02% | $0 M | Nov 16, 2026 |
| 92 | Advisory Alpha, LLC | 18,839 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 93 | New York State Common Retirement Fund | 18,209 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 94 | Integrated Wealth Concepts LLC | 17,202 | +300 (+1.77%) | 0.02% | $0 M | Nov 17, 2026 |
| 95 | Mariner, LLC | 16,963 | -50,172 (-74.73%) | 0.02% | $0 M | Nov 12, 2026 |
| 96 | China Universal Asset Management Co., Ltd. | 16,914 | +2,165 (+14.68%) | 0.02% | $0 M | Oct 28, 2026 |
| 97 | Delta Asset Management Llc/tn | 16,000 | 0 (0.00%) | 0.02% | $0 M | Nov 10, 2026 |
| 98 | StoneX Group Inc. | 15,313 | -3,366 (-18.02%) | 0.02% | $0 M | Nov 3, 2026 |
| 99 | Wealth Enhancement Advisory Services, LLC | 15,278 | -15,854 (-50.93%) | 0.02% | $0 M | Oct 13, 2026 |
| 100 | Prudential Financial Inc | 15,155 | 0 (0.00%) | 0.02% | $0 M | Nov 16, 2026 |
Mutual funds holding Anavex Life Sciences Corp.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 2.93 M | $8 M | 3.2% | <0.01% | +7.1% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 2.42 M | $6 M | 2.6% | <0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 Federated Hermes MDT Small Cap Core FundFederated Hermes MDT Series | 2.05 M | $6 M | 2.2% | 0.25% | +289% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 1.00 M | $3 M | 1.1% | <0.01% | +15% | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.04 M | $3 M | 1.1% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 737,460 | $2 M | 0.80% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 631,748 | $2 M | 0.68% | 0.02% | −5.5% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 484,708 | $1 M | 0.52% | <0.01% | +7.1% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 450,282 | $1 M | 0.49% | <0.01% | +8.5% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 440,209 | $1 M | 0.47% | <0.01% | +5.3% | May 31, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 266,123 | $1 M | 0.29% | <0.01% | +3.9% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 310,051 | $1 M | 0.33% | 0.05% | +40% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 224,867 | $1 M | 0.24% | <0.01% | +17% | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 175,983 | $1 M | 0.19% | <0.01% | +13% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 186,662 | $0 M | 0.20% | <0.01% | +32% | Jun 30, 2026 |
| 🇺🇸 iShares U.S. Small-Cap Equity Factor ETFBlackRock Fund Advisors | 161,530 | $0 M | 0.17% | 0.01% | −44% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 140,123 | $0 M | 0.15% | <0.01% | +13% | May 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 142,968 | $0 M | 0.15% | <0.01% | −80% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 122,064 | $0 M | 0.13% | <0.01% | +13% | Jul 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 123,215 | $0 M | 0.13% | <0.01% | +2.5% | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 123,000 | $0 M | 0.13% | 0.22% | new | Jun 30, 2026 |
| 🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc. | 95,522 | $0 M | 0.10% | 0.18% | +20% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 107,650 | $0 M | 0.12% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 100,888 | $0 M | 0.11% | <0.01% | +3.6% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 81,699 | $0 M | 0.09% | 0.01% | +7.0% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 68,920 | $0 M | 0.07% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 53,539 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC | 47,885 | $0 M | 0.05% | 0.09% | — | Apr 30, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 61,679 | $0 M | 0.07% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 61,470 | $0 M | 0.07% | <0.01% | +34% | Jun 30, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 56,923 | $0 M | 0.06% | <0.01% | +115% | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 58,700 | $0 M | 0.06% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 53,570 | $0 M | 0.06% | <0.01% | +41% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 49,361 | $0 M | 0.05% | <0.01% | +11% | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 48,976 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 46,081 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 48,289 | $0 M | 0.05% | <0.01% | +11% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 44,051 | $0 M | 0.05% | <0.01% | +20% | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 38,163 | $0 M | 0.04% | <0.01% | +17% | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 38,660 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 33,257 | $0 M | 0.04% | <0.01% | +1.8% | Jul 31, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 31,271 | $0 M | 0.03% | <0.01% | +84% | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 29,900 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 26,153 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/Common Stock Index PortfolioEquitable Investment Management Group, LLC | 23,900 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 21,397 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 22,386 | $0 M | 0.02% | <0.01% | +31% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 22,357 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 20,931 | $0 M | 0.02% | 0.02% | +33% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 20,441 | $0 M | 0.02% | <0.01% | +27% | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 19,700 | $0 M | 0.02% | <0.01% | −3.0% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 19,345 | $0 M | 0.02% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 15,300 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 16,591 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 14,445 | $0 M | 0.02% | <0.01% | −78% | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 14,432 | $0 M | 0.02% | <0.01% | +19% | Jun 30, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 14,396 | $0 M | 0.02% | <0.01% | −4.5% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 14,061 | $0 M | 0.02% | <0.01% | +33% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 13,159 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 12,731 | $0 M | 0.01% | <0.01% | +31% | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 12,007 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 10,379 | $0 M | 0.01% | <0.01% | +1.0% | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 10,612 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 9,594 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 8,592 | $0 M | <0.01% | <0.01% | +321% | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 8,422 | $0 M | <0.01% | <0.01% | −4.8% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 6,160 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 6,627 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 6,984 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 6,739 | $0 M | <0.01% | <0.01% | +23% | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 6,704 | $0 M | <0.01% | <0.01% | +28% | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 6,263 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 6,397 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 6,340 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 5,000 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 4,864 | $0 M | <0.01% | <0.01% | −66% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 4,671 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 4,119 | $0 M | <0.01% | <0.01% | +14% | May 31, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 3,505 | $0 M | <0.01% | <0.01% | −5.3% | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 3,258 | $0 M | <0.01% | <0.01% | −37% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 3,220 | $0 M | <0.01% | <0.01% | −38% | May 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 3,717 | $0 M | <0.01% | <0.01% | −45% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 3,585 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 3,186 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 2,431 | $0 M | <0.01% | <0.01% | −79% | Jun 30, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 2,410 | $0 M | <0.01% | <0.01% | +24% | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 2,026 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 2,253 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC | 1,840 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 1,635 | $0 M | <0.01% | <0.01% | +12% | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 1,378 | $0 M | <0.01% | <0.01% | −79% | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 1,221 | $0 M | <0.01% | <0.01% | −79% | Jul 31, 2026 |
| 🇺🇸 Nuveen Life Stock Index FundTeachers Advisors, LLC | 1,126 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc. | 545 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 521 | $0 M | <0.01% | <0.01% | +9.7% | Jul 31, 2026 |
| 🇺🇸 E*TRADE No Fee Total Market Index FundMorgan Stanley Investment Management Inc. | 40 | $0 M | <0.01% | <0.01% | — | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 96 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Anavex Life Sciences Corp.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Christopher U. MisslingPresident and CEO, Director | Option exercise | +187,500 | $5.040 | $945 K | 1.66 M | Form 4 |
| filed | Christopher U. MisslingPresident and CEO, Director | Shares withheld for tax | -145,048 | $9.580 | $1.4 M | 1.51 M | Form 4 |
| filed | Steffen ThomasDirector | Option exercise | +50,000 | $1.760 | $88 K | 55,000 | Form 4 |
| filed | Steffen ThomasDirector | Shares withheld for tax | -11,349 | $7.750 | $88 K | 43,651 | Form 4 |
| filed | Christopher U. MisslingPresident and CEO, Director | Option exercise | +500,000 | $0.920 | $460 K | 1.75 M | Form 4 |
| filed | Christopher U. MisslingPresident and CEO, Director | Shares withheld for tax | -282,497 | $9.630 | $2.7 M | 1.47 M | Form 4 |
| filed | Peter D.o. DonhauserDirector | Buy | +2,835 | $3.640 | $10 K | 5,000 | Form 4 |
| filed | Steffen ThomasDirector | Buy | +5,000 | $4.520 | $23 K | 5,000 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Anavex Life Sciences Corp.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2025-11-14 14:39 UTC, code LUDP, resumed 14:44 UTC
- 2025-11-14 14:33 UTC, code LUDP, resumed 14:38 UTC
Fails to deliver
- : 5 shares at $1.33
- : 778 shares at $1.36
- : 21,210 shares at $1.31
- : 2,971 shares at $1.49
- : 1 shares at $1.48
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Anavex Life Sciences Corp. scorecard#
Passes 1 of the 11 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 26, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.3×Price to book 1.3× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-2.2%Free cash flow is -2.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.54 vs -0.52Diluted EPS -0.54 in fiscal 2025 against -0.52 the year before (report's currency).
- ✗Net income higher than five years earlier-$46 M-$46 M in fiscal 2025 against -$26 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$46 MNet income -$46 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-43.1%-43.1% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 1
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year2.2%Diluted shares up 2.2% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Anavex Life Sciences Corp.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Sep 30, 2025 | FY 2024to Sep 30, 2024 | FY 2023to Sep 30, 2023 | FY 2022to Sep 30, 2022 | FY 2021to Sep 30, 2021 | FY 2020to Sep 30, 2020 | FY 2019to Sep 30, 2019 | FY 2018to Sep 30, 2018 | FY 2017to Sep 30, 2017 | FY 2016to Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Research and development | 38−10.1%— | 42−4.3%— | 44+15.3%— | 38r38+15.0%— | 33r33+30.7%— | 25+13.3%— | 22+66.8%— | 13+25.0%— | 11+47.1%— | 7.3—— | |
| Selling, general and administrative | 14+25.2%— | 11−8.4%— | 12—— | — | — | — | — | — | — | — | |
| General and administrative | 14+25.2%— | 11−8.4%— | 12r12−7.8%— | 13r13+44.9%— | 9.0r9.0+54.0%— | 5.9−14.5%— | 6.8+14.3%— | 6.0+19.6%— | 5.0−39.9%— | 8.3—— | |
| Operating expenses | 51−2.8%— | 53−5.2%— | 56r56+9.4%— | 51r−51+21.4%— | 42r42—— | −31r31−207%— | 29+50.6%— | 19+23.3%— | 16+0.6%— | 16—— | |
| Operating income | −51—— | −53—— | −56r−56—— | −51r−51—— | −42r−42—— | −31—— | — | — | — | — | |
| Net interest income | 4.7−36.1%— | 7.3+12.3%— | 6.5+588%— | 0.9r0.9+3542%— | 0.0r0.0−85.6%— | 0.2−13.2%— | 0.2−18.7%— | 0.3+190%— | 0.1+678%— | 0.0—— | |
| Other non-operating income (expense) | 5.0−49.1%— | 9.9+19.6%— | 8.3+145%— | 3.4r3.4−22.8%— | 4.4r4.4−9.7%— | 4.8+66.9%— | 2.9+34.4%— | 2.2r2.0−5.5%— | 2.3+158%— | 0.9—— | |
| Income before tax | −46—— | −43—— | −47—— | −48r−48—— | −38r−38—— | −26—— | −26—— | −17r−17—— | −13—— | −15—— | |
| Net income attributable to shareholders | −46—— | −43—— | −48—— | −48r−48—— | −38r−38—— | −26—— | −26—— | −17r−17—— | −13—— | −15—— | |
| Earnings per share, basic | -0.54—— | -0.52—— | -0.60—— | -0.62—— | -0.54—— | -0.45—— | -0.54—— | -0.39—— | -0.33—— | -0.42—— | |
| Earnings per share, diluted | -0.54—— | -0.52—— | -0.60—— | -0.62—— | -0.54—— | -0.45—— | -0.54—— | -0.39—— | -0.33—— | -0.42—— | |
| Shares, weighted average (basic) | 85+2.2%— | 83+4.6%— | 80+3.7%— | 77+10.2%— | 70—— | — | — | — | — | 35—— | |
| Shares, weighted average (diluted) | 85+2.2%— | 83+4.6%— | 80+3.7%— | 77+10.2%— | 70+19.9%— | 58+19.0%— | 49+9.5%— | 45+9.3%— | 41+16.2%— | 35—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 103−22.4%98.8% | 132−12.5%97.5% | 151+1.3%97.8% | 149r149−1.9%97.7% | 152+420%94.1% | 29+31.8%84.7% | 22−3.2%87.6% | 23−16.4%87.5% | 27+199%98.6% | 9.2—96.7% | |
| Other current assets | 0.4−53.9%0.4% | 0.9+42.6%0.7% | 0.7+84.5%0.4% | 0.4r0.4−4.8%0.2% | 0.4—0.2% | — | 0.5−60.0%2.0% | 1.3—4.8% | — | — | |
| Current assets | — | — | — | — | — | — | 25−2.8%100% | 26r24−6.2%99.4% | 28+194%99.8% | 9.4—99.4% | |
| Total assets | 104−23.4%100% | 136−12.2%100% | 154+1.1%100% | 153r153−5.5%100% | 162+368%100% | 35+36.4%100% | 25−3.3%100% | 26r24−5.9%100% | 28+193%100% | 9.5—100% | |
| Accounts payable | 4.2−55.9%4.1% | 9.6+123%7.1% | 4.3+13.0%2.8% | 3.8r3.8−19.3%2.5% | 4.7+18.8%2.9% | 4.0+13.2%11.5% | 3.5+19.2%13.9% | 3.0r3.9−17.5%11.3% | 3.6+14.9%12.9% | 3.1—32.8% | |
| Current liabilities | — | — | — | — | 11+47.8%6.7% | 7.3+45.0%21.1% | 5.0+29.7%19.9% | 3.9+8.4%14.8% | 3.6+12.3%12.9% | 3.2—33.6% | |
| Total liabilities | 8.9−41.5%8.6% | 15+22.1%11.3% | 13+22.7%8.1% | 10r10−5.4%6.7% | 11+47.8%6.7% | 7.3+45.0%21.1% | 5.0—19.9% | — | 3.6+12.3%12.9% | 3.2—33.6% | |
| Retained earnings | −382—−368% | −336—−248% | −293—−190% | −246r−246—−161% | −198—−122% | −160—−462% | −133—−527% | −107r−109—−409% | −91—−329% | −78—−821% | |
| Shareholders' equity | 95−21.1%91.4% | 120−15.2%88.7% | 142−0.4%91.9% | 142r142−5.5%93.3% | 151r151+454%93.3% | 27r27+34.2%78.9% | 20−9.1%80.1% | 22r20−13.8%85.2% | 26r24+310%93.0% | 6.3—66.4% | |
| Total liabilities and equity | 104−23.4%100% | 136−12.2%100% | 154+1.1%100% | 153r153−5.5%100% | 162+368%100% | 35+36.4%100% | 25−3.3%100% | 26r24−5.9%100% | 28+193%100% | 9.5—100% | |
| Shares outstanding | 87+2.2%— | 85+3.3%— | 82+5.3%— | 78+2.7%— | 76+22.4%— | 62+17.8%— | 53r53+14.6%— | 46+6.0%— | 43+19.8%— | 36—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | — | 0.0—— | |
| Share-based compensation | 12+22.4%— | 9.4−42.3%— | 16−10.9%— | 18r18+123%— | 8.2r8.2+68.8%— | 4.9−24.2%— | 6.4+16.6%— | 5.5+33.4%— | 4.1−18.3%— | 5.1—— | |
| Cash from operating activities | −39—— | −31—— | −28—— | −24r−24—— | −30r−30—— | −21—— | −19—— | −13—— | −9.0—— | −9.2—— | |
| Shares issued | — | 11−59.5%— | 28+32.8%— | 21r21−86.3%— | 153r153+433%— | 29+61.2%— | 18+118%— | 8.2−70.0%— | 27+761%— | 3.2—— | |
| Cash from financing activities | 9.4−21.2%— | 12−59.6%— | 30+39.3%— | 21r21−86.1%— | 153r153+441%— | 28+59.4%— | 18+120%— | 8.1−70.4%— | 27+771%— | 3.1—— | |
| Change in cash | — | — | — | — | — | 7.1—— | −0.7—— | — | — | — | |
| Report | 10-K/A | 10-K/A | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q3 FY2026to Jun 30, 2026 | Q2 FY2026to Mar 31, 2026 | Q1 FY2026to Dec 31, 2025 | Q4 FY2025to Sep 30, 2025 | Q3 FY2025to Jun 30, 2025 | Q2 FY2025to Mar 31, 2025 | Q1 FY2025to Dec 31, 2024 | Q4 FY2024to Sep 30, 2024 | Q3 FY2024to Jun 30, 2024 | Q2 FY2024to Mar 31, 2024 | Q1 FY2024to Dec 31, 2023 | Q4 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | — | — | 4.2−57.6%— | 4.7−55.4%— | 7.3*−37.2%— | 10.0−15.7%— | 9.9+1.7%— | 10+20.3%— | 12r12*+15.4%— | 12r12—— | 9.7—— | 8.7—— | 10r10*—— | |
| Selling, general and administrative | 10—— | 2.0−54.8%— | 2.3−12.6%— | 2.1−32.4%— | 3.6*—— | 4.5—— | 2.6—— | 3.1—— | — | — | — | — | — | |
| General and administrative | — | — | 2.3−12.6%— | 2.1−32.4%— | 3.6*+33.6%— | 4.5+61.2%— | 2.6−9.5%— | 3.1+16.8%— | 2.7r2.8*+2.2%— | 2.8r2.9—— | 2.9r2.8—— | 2.7r2.6—— | 2.6r2.6*—— | |
| Operating expenses | 17−68.3%— | −6.7−147%— | 6.5−48.2%— | 6.8−50.1%— | 11*−24.0%— | 14−1.0%— | 13−0.9%— | 14+19.5%— | 14r14*+12.7%— | 15r15—— | 13r13—— | 11r11—— | 13r13*—— | |
| Operating income | −17—— | 6.7—— | −6.5—— | −6.8—— | −11*—— | −14—— | −13—— | −14—— | −14r−14*—— | −15r−15—— | −13r−13—— | −11r−11—— | −13r−13*—— | |
| Net interest income | 4.2−22.6%— | 1.1−0.3%— | 1.1−12.3%— | 1.1−22.6%— | 1.0*−43.2%— | 1.1−40.1%— | 1.2−31.1%— | 1.4−30.6%— | 1.8*−10.2%— | 1.8—— | 1.8—— | 2.0—— | 2.0r2.0*—— | |
| Other non-operating income (expense) | 4.4−34.4%— | 1.1−10.6%— | 1.1−13.0%— | 1.1−24.4%— | 1.0*−61.6%— | 1.2−49.1%— | 1.3−36.6%— | 1.5−46.3%— | 2.7r2.6*+8.6%— | 2.4r2.4—— | 2.1—— | 2.8—— | 2.4r2.4*—— | |
| Income before tax | — | — | — | — | — | — | — | — | −12*—— | −12—— | −10—— | −8.5—— | −10r−10*—— | |
| Income tax | — | 0*—— | 0*—— | 0.0—— | — | — | — | — | — | — | — | — | — | |
| Net income attributable to shareholders | −13—— | 7.8—— | −5.3—— | −5.7—— | −9.8*—— | −13—— | −11—— | −12—— | −12*—— | −12—— | −11—— | −8.6—— | −10r−10*—— | |
| Earnings per share, basic | — | 0.08—— | -0.06—— | -0.06—— | — | -0.16—— | -0.13—— | -0.14—— | — | -0.14—— | -0.13—— | -0.11—— | — | |
| Earnings per share, diluted | — | 0.08—— | -0.06—— | -0.06—— | — | -0.16—— | -0.13—— | -0.14—— | — | -0.14—— | -0.13—— | -0.11—— | — | |
| Shares, weighted average (basic) | 92,697+8.6%— | 92,697+8.6%— | 93+8.9%— | 89+5.0%— | — | 85,381r85+100900%— | 85+3.2%— | 85+3.3%— | — | 85—— | 82—— | 82—— | — | |
| Shares, weighted average (diluted) | 92,900+8.8%— | 92,900+8.8%— | 93+8.9%— | 89+5.0%— | — | 85,381r85+100900%— | 85+3.2%— | 85+3.3%— | — | 85—— | 82—— | 82—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 118—98.5% | 118+17.0%98.5% | 127+10.1%99.0% | 132+9.1%99.1% | 103−22.4%98.8% | 101−27.1%98.8% | 116−16.9%98.8% | 121−16.0%97.4% | 132−12.5%97.5% | 139—98.0% | 139—96.5% | 144—97.1% | 151—97.8% | |
| Other current assets | 0.8—0.7% | 0.8+82.6%0.7% | 0.4−41.3%0.3% | 0.4−44.3%0.3% | 0.4−53.9%0.4% | 0.4−57.7%0.4% | 0.7−47.8%0.6% | 0.7−6.0%0.6% | 0.9+42.6%0.7% | 1.1—0.7% | 1.3—0.9% | 0.8—0.5% | 0.7—0.4% | |
| Total assets | 120—100% | 120+17.3%100% | 129+9.9%100% | 133+7.2%100% | 104−23.4%100% | 102−27.6%100% | 117−18.9%100% | 124−16.2%100% | 136−12.2%100% | 142—100% | 145—100% | 148—100% | 154—100% | |
| Accounts payable | 3.7—3.0% | 3.7−45.8%3.0% | 2.5−64.0%2.0% | 2.6−42.2%2.0% | 4.2−55.9%4.1% | 6.7+92.4%6.6% | 7.0+87.8%6.0% | 4.6+6.4%3.7% | 9.6+123%7.1% | 3.5—2.5% | 3.7—2.6% | 4.3—2.9% | 4.3—2.8% | |
| Total liabilities | 7.7—6.4% | 7.7−33.0%6.4% | 7.1−59.4%5.5% | 6.4−51.5%4.8% | 8.9−41.5%8.6% | 11−2.4%11.2% | 17+81.8%14.8% | 13+5.1%10.6% | 15+22.1%11.3% | 12—8.3% | 9.6—6.6% | 12—8.4% | 13—8.1% | |
| Retained earnings | −386—−321% | −386—−321% | −393—−306% | −388—−292% | −382—−368% | −373—−364% | −359—−307% | −348—−281% | −336—−248% | −324—−229% | −312—−216% | −302—−204% | −293—−190% | |
| Shareholders' equity | 112—93.6% | 112+23.6%93.6% | 122+22.0%94.5% | 127+14.2%95.2% | 95−21.1%91.4% | 91−29.9%88.8% | 100−26.1%85.2% | 111−18.2%89.4% | 120−15.2%88.7% | 130—91.7% | 135—93.4% | 136—91.6% | 142—91.9% | |
| Total liabilities and equity | 120—100% | 120+17.3%100% | 129+9.9%100% | 133+7.2%100% | 104−23.4%100% | 102−27.6%100% | 117−18.9%100% | 124−16.2%100% | 136−12.2%100% | 142—100% | 145—100% | 148—100% | 154—100% | |
| Shares outstanding | 93—— | 93+8.5%— | 93+8.6%— | 93+9.0%— | 87+2.2%— | 85+0.7%— | 85+2.1%— | 85+3.5%— | 85+3.3%— | 85—— | 84—— | 82—— | 82—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | −12−221%— | −17−495%— | 0.3−78.3%— | 1.1−46.1%— | 3.7*+84.8%— | 4.3+73.8%— | 1.4−45.4%— | 2.1−10.1%— | 2.0*−36.8%— | 2.5—— | 2.7—— | 2.3—— | 3.2r3.2*—— | |
| Cash from operating activities | −29—— | −9.1*—— | −4.4*—— | −7.2—— | −8.6*—— | −12*—— | −5.9*—— | −12—— | −6.7*—— | −5.2*—— | −12*—— | −7.3—— | −5.8r−5.8*—— | |
| Shares issued | — | — | — | — | — | — | — | — | 0*−100%— | 4.1*—— | — | — | 1.2r1.2*—— | |
| Cash from financing activities | 46—— | 0*—— | 0.1*−86.7%— | 36+5030%— | 10*+11155%— | −2.1*−147%— | 0.9*−88.3%— | 0.7+1100%— | 0.1*−95.7%— | 4.6*—— | 7.3*—— | 0.1—— | 2.1r2.1*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K/A | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Anavex Life Sciences Corp. operates: 3 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office | — |
| 🇦🇺 Australia | 1 subsidiary | — |
| 🇩🇪 Germany | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at Anavex Life Sciences Corp.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Change in control 1 · Directors and officers 7 · Material agreement 1 · Agreement ended 1 · Shareholder vote 3 · Results announced 4
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Change in controlShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Agreement ended | 8-K | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 3, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2014 | $10 M | Private placement after listing | $10 to $50 million | 11 | debt, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Anavex Life Sciences Corp.#
$240 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.
- Health Issues4 reports
Lobbying firms hired in 2025
Forbes-Tate $240 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $0 | — | 1 |
| 2025 | $240 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Anavex Life Sciences”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How Anavex Life Sciences Corp. compares in Biotechnology
- Market cap$123 M · higher than 39% of 726
- Price / book1.3× · lower than 71% of 534
- FCF yield-2.2% · higher than 80% of 449
- 🇺🇸 Foghorn Therapeutics Inc.$123 M
- 🇹🇼 Mycenax Biotech Inc.$124 M
- 🇺🇸 Humacyte, Inc.$125 M
- 🇺🇸 Nkarta, Inc.$125 M
- 🇺🇸 Immunic, Inc.$121 M
- 🇹🇼 Medigen Biotechnology Corp.$120 M
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Anavex Life Sciences Corp.🇺🇸 | $123 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 26, 2026
- Annual results:
- For year ending September-2025
- Balance sheet:
- As of September-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Anavex Life Sciences Corp.? Verify and update this profile — free
Show Anavex Life Sciences Corp.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.